Worth reading
36Immaterial
Scored from 4 of 6 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Results for this period
First quarter2024年9月1日〜2024年11月30日ConsolidatedJapanese GAAPNet Sales7,655¥ millionYear on year +7.6%
Operating profit2,107¥ millionYear on year -5.2%
Ordinary income2,298¥ millionYear on year -2.2%
Net income attributable to owners of the parent1,598¥ millionYear on year +1.6%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets57,334¥ million
of which net assets 52,345 ¥ million
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Segment revenueSurgical-related products ¥2,442 million (YoY +25.5%), Ailess needle-related products ¥2,844 million (YoY +12.9%), Dental Products ¥2,368 million (YoY -10.6%)
Segment profitSurgical-related products ¥838 million (YoY +28.8%), Ailess needle-related products ¥1,046 million (YoY +8.2%), Dental Products ¥222 million (YoY -63.2%)
Regional sales¥1,152 million, ¥3,440 million, ¥1,500 million, ¥760 million, ¥800 million
Factors Behind Changes in Business Performance
欧州地域でサージカル関連製品、中国を中心としたアジア地域でアイレス針関連製品の販売が増加した一方、中国でデンタル関連製品の販売が低調に推移した。決算賞与の計上や人件費等の増加で販売費及び一般管理費が増加し、法人税等調整額の減少で最終利益が増加した。
Disclosure regarding the going concern assumption
No applicable matters
Material subsequent eventsNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥12 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥0 million, Other ¥3 million
Depreciation and amortization¥569 million
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年9月1日〜2024年11月30日 |
| Net Sales | ¥7,655 million (YoY +7.6%) |
| Operating profit | ¥2,107 million (YoY -5.2%) |
| Ordinary income | ¥2,298 million (YoY -2.2%) |
| Profit attributable to owners of the parent | ¥1,598 million (YoY +1.6%) |
| Total assets | ¥57,334 million |
| Net assets | ¥52,345 million |
| Segment revenue | Surgical-related products ¥2,442 million (YoY +25.5%), Ailess needle-related products ¥2,844 million (YoY +12.9%), Dental Products ¥2,368 million (YoY -10.6%) |
| Segment profit | Surgical-related products ¥838 million (YoY +28.8%), Ailess needle-related products ¥1,046 million (YoY +8.2%), Dental Products ¥222 million (YoY -63.2%) |
| Regional sales | ¥1,152 million, ¥3,440 million, ¥1,500 million, ¥760 million, ¥800 million |
| Depreciation and amortization | ¥569 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥12 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥0 million, Other ¥3 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Material subsequent events | No applicable matters. |
| Factors Behind Changes in Business Performance | 欧州地域でサージカル関連製品、中国を中心としたアジア地域でアイレス針関連製品の販売が増加した一方、中国でデンタル関連製品の販売が低調に推移した。決算賞与の計上や人件費等の増加で販売費及び一般管理費が増加し、法人税等調整額の減少で最終利益が増加した。 |
Items this document does not state (20)
Net income per shareOperating MarginEquity ratioCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyOrders received and order backlogImpairment lossChange in accounting policyChanges in the scope of consolidationAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The interim review of the quarterly consolidated financial statements by certified public accountants, etc. has been completed.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.